Oritavancin (Tenkasi®). HTA ID: 21061

Assessment Status Rapid Review Complete
HTA ID 21061
Drug Oritavancin
Brand Tenkasi®
Indication For the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Assessment Process
Rapid review commissioned 07/12/2021
Rapid review completed 24/01/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of oritavancin compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.

The HSE has approved reimbursement following confidential price negotiations June 2022.